公开(公告)号：US12233065B2

公开(公告)日：2025-02-25

申请号：US18620110

申请日：2024-03-28

Applicant: ACCENT THERAPEUTICS, INC.

Inventor： Matthew H. Daniels ,  Kenneth W. Duncan ,  Brian Andrew Sparling ,  Andrew Stewart Tasker ,  Gavin Whitlock

IPC: A61K31/506 ,  A61K31/18 ,  A61K31/277 ,  A61K31/341 ,  A61K31/381 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/675 ,  A61P35/00 ,  C07C311/08 ,  C07D207/34 ,  C07D213/56 ,  C07D231/12 ,  C07D231/14 ,  C07D233/90 ,  C07D307/68 ,  C07D333/38 ,  C07D333/70 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07F9/6558

Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

公开(公告)号：US20250017880A1

公开(公告)日：2025-01-16

申请号：US18902504

申请日：2024-09-30

Applicant: REMEDY PHARMACEUTICALS, INC.

Inventor： Sven Martin JACOBSON

IPC: A61K31/18 ,  A61K9/00 ,  A61K31/166 ,  A61K31/451 ,  A61K31/64 ,  A61K47/26

Abstract: The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.

公开(公告)号：US12178791B2

公开(公告)日：2024-12-31

申请号：US17265402

申请日：2019-08-02

Applicant: Syntara Limited

Inventor： Alison Dorothy Findlay ,  Craig Ivan Turner ,  Mandar Deodhar ,  Jonathan Stuart Foot ,  Wolfgang Jarolimek ,  Wenbin Zhou ,  Alberto Buson ,  Angelique Elsa Greco

IPC: C07D209/08 ,  A61K31/145 ,  A61K31/18 ,  A61K31/4409 ,  A61K31/47 ,  A61P17/02 ,  A61P19/04 ,  A61P35/00 ,  A61P35/04 ,  C07C311/29 ,  C07C317/32 ,  C07D213/71 ,  C07D215/36 ,  C07D277/64

Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.

公开(公告)号：US20240390375A1

公开(公告)日：2024-11-28

申请号：US18796094

申请日：2024-08-06

Applicant: VIRACTA SUBSIDIARY, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

Inventor： Ronald J. Berenson ,  Douglas V. Faller

IPC: A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US20240376062A1

公开(公告)日：2024-11-14

申请号：US18696335

申请日：2022-09-27

Applicant: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY

Inventor： Jessica Sonia Fortin

IPC: C07D277/66 ,  A61K31/18 ,  A61K31/381 ,  A61K31/404 ,  A61K31/428 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/54 ,  C07C311/21 ,  C07D209/08 ,  C07D215/38 ,  C07D277/82 ,  C07D295/135 ,  C07D333/34

Abstract: Sulfonylamide and sulfonyl urea compounds, pharmaceutical compositions comprising same, and methods of treating diseases or disorders associated to amyloidogenesis activity with such compounds are disclosed.

公开(公告)号：US20240358710A1

公开(公告)日：2024-10-31

申请号：US18755609

申请日：2024-06-26

Applicant: AF Chemicals, LLC

Inventor： MICHAEL KELNER

IPC: A61K31/5375 ,  A61K31/047 ,  A61K31/121 ,  A61K31/122 ,  A61K31/135 ,  A61K31/15 ,  A61K31/16 ,  A61K31/18 ,  A61K31/192 ,  A61K31/198 ,  A61K31/351 ,  A61K31/357 ,  A61K31/401 ,  C12Q1/6886

CPC classification number: A61K31/5375 ,  A61K31/047 ,  A61K31/121 ,  A61K31/122 ,  A61K31/135 ,  A61K31/15 ,  A61K31/16 ,  A61K31/18 ,  A61K31/192 ,  A61K31/198 ,  A61K31/351 ,  A61K31/357 ,  A61K31/401 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: In an embodiment of the invention, a method of treating cancer includes screening to select a patient population that will respond to an Illudofulvene Analog composition based on the presence of one or more Transcription Coupled Repair (TCR) mutations, deletions or other events interfering with TCR biomarker expression in combination with upregulation of Myc and/or PTGR biomarker expression and treating the patient population with the Illudofulvene Analog composition.

公开(公告)号：US12128034B2

公开(公告)日：2024-10-29

申请号：US17198335

申请日：2021-03-11

Applicant: Iterum Therapeutics International Limited

Inventor： Michael Dunne

IPC: A61K31/431 ,  A61K9/00 ,  A61K9/20 ,  A61K31/18 ,  A61K31/19

CPC classification number: A61K31/431 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/2086 ,  A61K31/18 ,  A61K31/19

Abstract: The present disclosure relates to combinations of valproic acid or a pharmaceutically acceptable salt thereof, a β-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the combinations.

公开(公告)号：US20240350569A1

公开(公告)日：2024-10-24

申请号：US18763681

申请日：2024-07-03

Applicant: Houn Simon Hsia

Inventor： Houn Simon Hsia

IPC: A61K36/064 ,  A23L33/105 ,  A23L33/115 ,  A23L33/14 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/175 ,  A61K31/015 ,  A61K31/05 ,  A61K31/122 ,  A61K31/18 ,  A61K31/198 ,  A61K31/202 ,  A61K31/24 ,  A61K31/30 ,  A61K31/32 ,  A61K31/34 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/593 ,  A61K33/18 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K35/60 ,  A61K36/06

CPC classification number: A61K36/064 ,  A23L33/105 ,  A23L33/115 ,  A23L33/14 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/175 ,  A61K31/015 ,  A61K31/05 ,  A61K31/122 ,  A61K31/18 ,  A61K31/198 ,  A61K31/202 ,  A61K31/24 ,  A61K31/30 ,  A61K31/32 ,  A61K31/34 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/593 ,  A61K33/18 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K35/60 ,  A61K36/06 ,  A23V2002/00

Abstract: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer.

公开(公告)号：US12109183B2

公开(公告)日：2024-10-08

申请号：US17453432

申请日：2021-11-03

Applicant: Lanny Leo Johnson

Inventor： Lanny Leo Johnson

IPC: A61K31/192 ,  A61K31/18 ,  A61P31/18

CPC classification number: A61K31/192 ,  A61P31/18

Abstract: In embodiments, a method of treating a disease or condition caused by an enveloped virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals and disrupting the viral envelope of the enveloped virus. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier. The enveloped virus may be a coronavirus. The enveloped virus may be a virus of the family Orthomyxoviridae.

公开(公告)号：US20240327339A1

公开(公告)日：2024-10-03

申请号：US18577631

申请日：2022-07-06

Applicant: University of Georgia Research Foundation, Inc.

Inventor： Ralph A. Tripp ,  Jackelyn Murray ,  Devi Kalyan Karumanchi ,  David Eugene Martin

IPC: C07C311/16 ,  A23K20/111 ,  A23K50/30 ,  A23K50/75 ,  A61K31/18 ,  A61P31/14

CPC classification number: C07C311/16 ,  A23K20/111 ,  A23K50/30 ,  A23K50/75 ,  A61K31/18 ,  A61P31/14

Abstract: Probenecid prodrug compounds, and formulations including one or more of probenecid, metabolites and analogs thereof, and prodrugs thereof, and pharmaceutically acceptable salt thereof are provided. Delivery vehicles and pharmaceutical compositions including any of the foregoing are also provided. Methods of using the compounds and compositions to treat viral infections are also provided. In some embodiments, the viral infection is caused by an RNA virus. Particular viruses include, but are not limited to, influenza virus A, influenza virus B, or influenza virus C, respiratory syncytial virus (RSV), coronaviruses, measles virus, mumps virus, Zika virus, and dengue virus. Dosage regimens are also provided.